Weight Management Medication Cessation Leads to Weight Regain, Reversal of Cardiometabolic Benefits

A systematic review and meta-analysis published in BMJ found that cessation of weight management medications (WMMs) is followed by rapid weight regain and reversal of beneficial effects on cardiometabolic markers. The analysis included 37 studies with 9341 participants and revealed that weight regain occurs at an average monthly rate of 0.4 kg (95% CI, 0.3-0.5 kg), with patients projected to return to baseline weight approximately 1.7 years after stopping treatment.¹

Rapid Weight Regain Following Treatment Cessation

The meta-analysis examined data from trials with an average treatment duration of 39 weeks and an average follow-up of 32 weeks after medication cessation. For all WMMs combined, patients lost an average of 8.3 kg (95% CI, 7.2-9.5 kg) during active treatment; however, the mixed-model analysis estimated weight regain of 4.8 kg (95% CI, 3.6-6.0 kg) within the first year after stopping treatment. Among the newer and more effective incretin mimetics semaglutide (Wegovy; Novo Nordisk) and tirzepatide (Zepbound; Eli Lilly and Company), patients lost an average of 14.7 kg (95% CI, 11.1-18.4 kg) during treatment but were projected to regain 9.9 kg (95% CI, 8.4-10.8 kg) within the first year after cessation, with an estimated return to baseline weight by 1.5 years (95% CI, 1.0-1.9 years).¹

In randomized controlled trials comparing WMM groups with control groups, the time to no difference between intervention and control was estimated at 1.4 years (95% CI, 0.9-1.8 years) for all WMMs, 1.1 years (95% CI, 0.6-1.5 years) for incretin mimetics, and 1.3 years (95% CI, 0.8-1.8 years) for newer incretin mimetics. These findings suggest that the clinical benefits achieved during active treatment dissipate relatively quickly after discontinuation.¹

Reversal of Cardiometabolic Improvements

Beyond weight regain, the analysis revealed concerning patterns in cardiometabolic markers after treatment cessation. Glycated hemoglobin A_1c levels decreased by about 0.9 mmol/mol (95% CI, 0.5-1.3 mmol/mol) during active treatment but then increased at a monthly rate of 0.05 mmol/mol (95% CI, 0.03-0.08 mmol/mol) after cessation. Fasting glucose levels decreased by 0.5 mmol/L (95% CI, 0.3-0.7 mmol/L) during treatment and increased by 0.06 mmol/L (95% CI, 0.03-0.08 mmol/L) monthly after stopping.¹

Blood pressure improvements also reversed after medication cessation. Systolic blood pressure decreased by 5.8 mm Hg (95% CI, 3.6-7.9 mm Hg) during active treatment but increased at a monthly rate of 0.5 mm Hg (95% CI, 0.3-0.7 mm Hg) after cessation. Diastolic blood pressure decreased by 3.7 mm Hg (95% CI, 1.9-5.5 mm Hg) during treatment and increased by 0.2 mm Hg (95% CI, 0.1-0.3 mm Hg) monthly after stopping. Total cholesterol and triglyceride concentrations followed similar patterns. Ultimately, all cardiometabolic markers were projected to return to baseline within 1.4 years after cessation of WMM.¹

Comparison With Behavioral Weight Management Programs

The analysis compared weight regain after WMMs with data from a previous systematic review of behavioral weight management programs (BWMPs). Although WMMs produced greater initial weight loss than BWMPs (3.2 kg greater on average [95% CI, 2.1-4.3 kg; P < .001]), monthly weight regain was significantly faster after WMM cessation (0.3 kg faster per month [95% CI, 0.22-0.34 kg; P < .001]). Body weight after BWMPs was predicted to return to baseline 3.9 years (95% CI, 2.8-4.9 years) after treatment end, compared with only 1.7 years (95% CI, 1.3-2.1 years) after WMM. This difference persisted even when controlling for initial weight loss.¹

Real-World Discontinuation Rates

The clinical significance of these findings is amplified by high discontinuation rates observed in real-world practice. Recent studies report that approximately 50% of patients discontinue glucagon-like peptide-1 receptor agonists (GLP-1 RAs) within 12 months of initiation. A 2025 cohort study found that among adults with overweight or obesity, 64.8% of those without type 2 diabetes discontinued GLP-1 RA therapy within 1 year.^2,3

Real-world effectiveness data demonstrate the impact of early discontinuation on weight outcomes. In one observational study, patients who discontinued semaglutide or tirzepatide within the first 3 months lost only 3.6% of their body weight, whereas those who discontinued between 3 and 12 months lost 6.8%. In contrast, patients who remained adherent achieved weight loss of 11.9%, approaching clinical trial results.⁴

Obesity as a Chronic Disease: What This Means for Pharmacists

The American Diabetes Association Standards of Care recognize obesity as a chronic, relapsing disease like that of hypertension that typically requires continuation of pharmacotherapy after weight reduction goals are achieved to sustain weight loss and health benefits. The 2026 standards emphasize that, unless clinical circumstances or other considerations suggest otherwise, patients who achieve sufficient early weight loss (typically greater than 5% after 3 months) should continue medication long-term.⁵

Pharmacists play a critical role in educating patients about the chronic nature of obesity and the importance of long-term medication adherence. When dispensing WMMs, pharmacists should counsel patients that these medications are generally intended for chronic use and that discontinuation typically leads to weight regain. This conversation should occur at treatment initiation and be reinforced at subsequent refills.

Pharmacists should monitor for early discontinuation by tracking refill patterns and proactively reaching out to patients who miss refills. When patients express concerns about cost, adverse effects, or other barriers to continuation, pharmacists can facilitate communication with prescribers to explore solutions such as dose adjustments, alternative agents, or patient assistance programs.

For patients who do discontinue WMMs, pharmacists should provide counseling on the likelihood of weight regain and the importance of maintaining lifestyle modifications, including dietary changes and physical activity. Referrals to dietitians, behavioral health specialists, or structured weight management programs may help mitigate weight regain after medication cessation.

REFERENCES

1. West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. doi:10.1136/bmj-2025-085304

2. Thomsen RW, Mailhac A, Løhde JB, et al. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27(suppl 2):66-88. doi:10.1111/dom.16364

3. Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1):e2457349. doi:10.1001/jamanetworkopen.2024.57349

4. Gasoyan H, Butsch WS, Schulte R, et al. Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity. 2025;33(9):1657-1667. doi:10.1002/oby.24331

5. American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1):S166-S183. doi:10.2337/dc26-S008